(NASDAQ: XNCR) Xencor's forecast annual revenue growth rate of 5.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Xencor's revenue in 2026 is $104,973,000.On average, 16 Wall Street analysts forecast XNCR's revenue for 2026 to be $7,165,511,222, with the lowest XNCR revenue forecast at $1,020,128,607, and the highest XNCR revenue forecast at $15,598,599,157. On average, 16 Wall Street analysts forecast XNCR's revenue for 2027 to be $7,694,833,056, with the lowest XNCR revenue forecast at $1,092,994,936, and the highest XNCR revenue forecast at $18,308,036,943.
In 2028, XNCR is forecast to generate $9,280,047,480 in revenue, with the lowest revenue forecast at $4,259,036,934 and the highest revenue forecast at $26,427,427,896.